Skip to main content
Log in

The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Seminary

Inhibition of catechol catechol-O-methyltransferase (COMT) in the brains of subjects treated with l-DOPA (l-3,4-dihydroxylphenylalanine) and an aromatic amino acid decarboxylase (AADC) inhibitor is suggested to cause an increase of l-DOPA, which might lead to oxidative damage through enhanced formation of free radicals. To investigate this hypothesis, the acute effects of two doses of the systemically administered COMT inhibitors entacapone (peripheral) and tolcapone (peripheral and central) on the extracellular formation of hydroxyl radicals in vivo following treatment with l-DOPA and the AADC inhibitor carbidopa were examined. The formation of extracellular hydroxyl radicals were determined by the measurement of 2,3-dihydroxybenzoic acid (2,3-DHBA), a reaction product of hydroxyl radicals with sodium salicylate, using microdialysis in the striatum of anesthetised rats. The COMT inhibitors were administered together with 50mg/kg i.p. carbidopa as 5% gum arabic suspensions intraperitoneally (i.p.) at doses of 0, 1.0, and 10mg/kg body weight to a total of 36 male HAN-Wistars rats, l-DOPA was injected i.p. 40min after drugs of interest. Microdialysis samples were collected every 20 min for 400 min at a perfusion rate of 1µl/min. Systemically administered 10mg/kg tolcapone, but not entacapone, induced an increase in hydroxyl radical formation in the striatum of anesthetised rats following treatment with l-DOPA/carbidopa. The increase in hydroxyl radical formation was reflected by higher extracellular concentrations of the hydroxylate product of salicylate, 2,3-DHBA, peaking at 192% of baseline at the end of the observation period. Similar results were also found using the AUC (area under the curve) value estimated for the observation period. We conclude that the increase in hydroxyl radical formation is likely to result from an increased rate of monoamine oxidase-mediated and non-enzymatic (autoxidation) dopamine metabolism following increased central availability caused by reduction in COMT-mediated metabolism. We cannot, however, exclude the possibility that hydroxyl radicals are produced by tolcapone as a result of uncoupling mitochondrial oxidative phosphorylation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ADDC :

aromatic amino acid decarboxylase

AUC :

area under the curve

ANOVA :

analysis of variance

COMT :

catechol-O-methyltransferase

2,3-DHBA :

2,3-dihydroxybenzoic acid

l-DOPA:

levodopa, l-3,4-didydroxylphenylalanine

DOPAC :

3,4-dihydroxyphenylacetic acid

HPLC :

high pressure liquid chromatography

HVA :

homovanillic acid

i.p. :

intraperitoneally

MAO :

monoamine oxidase

3-MT :

3-methoxytyramine

NMDA :

N-methyl-d-aspartate

OMD :

3-O-metyl-DOPA

PD :

Parkinson’s disease

SPECT :

single photon emission computed tomography

References

  • Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525: 36–40

    Article  PubMed  CAS  Google Scholar 

  • Acquas E, Carboni E, De Ree RAH, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40,7592. J Neurochem 59: 326–330

    Article  PubMed  CAS  Google Scholar 

  • Brannan T, Prikhojan A, Yahr MD (1997) Peripheral and central inhibitors of catechol-O-methyltransferase: effects on liver and brain COMT activity and l-DOPA metabolism. J Neural Transm 104: 77–87

    Article  PubMed  CAS  Google Scholar 

  • Brown EE, Damsma G, Gumming P, Fibiger HC (1991) Interstitial 3-methoxytyrarnine reflects striatal dopamine release: an in vivo microdialysis study. J Neurochem 57: 701–707

    Article  PubMed  CAS  Google Scholar 

  • Camp DM, Loeffler DA, Le Witt PA (2000) l-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with unilateral 6-hydroxydop- amine lesion. J Neurochem 74: 1229–1240

    PubMed  CAS  Google Scholar 

  • Fahn S (1997) Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 8: 376–393

    Article  CAS  Google Scholar 

  • Gerlach M, Xiao A, Heim C, Lan J, God R, Feineis D, Bringmann G, Riederer P, Sontag K-H (1998) l-Trichloromethyl-l,2,3,4-tetrahydro-²-carboline (TaClo) increases extracellular serotonin and stimulates hydroxyl radical production. Neurosci Lett 257: 17–20

    Article  PubMed  CAS  Google Scholar 

  • Götz ME, Kiinig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neuronal degeneration. Pharmac Ther 63: 37–122

    Article  Google Scholar 

  • Kaakkola S, Wurtman RJ (1992) Effects of catechol-O-methyltransferase inhibitors on striatal dopamine metabolism. Brain Res 587: 241–249

    Article  PubMed  CAS  Google Scholar 

  • Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137–144

    Article  PubMed  CAS  Google Scholar 

  • Kaakkola S, Gordin A, Männistö PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 25: 813–824

    PubMed  CAS  Google Scholar 

  • Karhunen T, Tilgmann C, Ulmanen I, Panula P (1995) Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 187: 57–60

    Article  PubMed  CAS  Google Scholar 

  • Kastner A, Anglade P, Damier P, Javoy-Agid F, Bromet N, Agid Y, Hirsch EC (1994) Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neuroscience 62: 449–457

    Article  PubMed  CAS  Google Scholar 

  • Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T (1998) Tolcapone and neurotoxicity in Parkinson’s disease. Lancet 352: 1313–1314

    Article  PubMed  CAS  Google Scholar 

  • Männistö PT, Tuomainen P, Tuominen RK (1992a) Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 105: 569–574

    PubMed  Google Scholar 

  • Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Kaakkola S (1992b) Characteristics of catechol-O-methyltransferase (COMT) and properties of selective inhibitors. Prog Drug Res 39: 291–350

    PubMed  Google Scholar 

  • McNeely W, Davis R (1997) Entacapone. CNS Drugs 8: 79–88

    Article  CAS  Google Scholar 

  • Montastruc JL, Rascol O, Senard JM (1999) Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord 14: 725–730

    Article  PubMed  CAS  Google Scholar 

  • Montgomery J, Ste-Marie L, Boismenu D, Vachon L (1995) Hydroxylation of aromatic compounds as indices of hydroxyl radical production: a cautionary note revisited. Free Radie Biol Med 19: 927–933

    Article  CAS  Google Scholar 

  • Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Jkola O, Heinonen EH (1997) Selegiline as the primary treatment of Parkinson’s disease — a long-term double-blind study. Acta Neurol Scand 95: 211–218

    Article  PubMed  Google Scholar 

  • Napolitano A, Zürcher G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of l-DOPA and dopamine in rats. Eur J Pharmacol 273: 215–221

    Article  PubMed  CAS  Google Scholar 

  • Nissinen E, Kaheinen P, Penttilä KE, Kaivola J, Linden I-B (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur J Pharmacol 340: 287–294

    Article  PubMed  CAS  Google Scholar 

  • Patthy M, Kiraly I, Sziraki I (1995) Separation of dihydroxybenzoates, indicators of in-vivo hydroxyl free radical formation, in the presence of transmitter amines and some metabolites in rodent brain, using high performance liquid chromatography with electrochemical detection. J Chromatogr B 664: 247–252

    Article  CAS  Google Scholar 

  • Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates, 2nd ed. Academic Press, London

    Google Scholar 

  • Spencer CM, Benfield P (1996) Tolcapone. CNS Drugs 5: 475–481

    Article  CAS  Google Scholar 

  • Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G (2000) Measuring the progression of idiopathic Parkinson’s disease with [I-123] beta-CIT SPECT. J Neural Transm 107: 543–552

    Article  PubMed  CAS  Google Scholar 

  • Wachtel SR, Abercrombie ED (1994) l-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108–117

    Article  PubMed  CAS  Google Scholar 

  • Zürcher G, Dingemanse J, Da Prada M (1991) Ro-40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G (eds) New developments in therapy of Parkinson’s disease. John Libbey CIC, Roma, pp 37–43

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerlach, M., Xiao, A.Y., Kuhn, W. et al. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats. J Neural Transm 108, 189–204 (2001). https://doi.org/10.1007/s007020170087

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007020170087

Keywords

Navigation